Ex-biotech CEO to pay SEC more than $1.1m
Agency says he misled investors about drug
A former Transkaryotic Therapies Inc. executive agreed to pay more than $1.1 million to settle claims that he misled investors about problems facing the Cambridge biotech company's flagship drug, the government said yesterday. (Full article: 389 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
